Study of ALN-2232 in people with obesity
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests an investigational drug called ALN-2232 in people with obesity to see if it can help with weight management. You may be able to join if you have a BMI between 30 and 40 and do not have diabetes or take other weight-loss or diabetes medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your body mass index (BMI) is between 30 and 40
- Your blood sugar level (HbA1c) is below 6.5%, meaning you do not have diabetes
- You are not currently taking any medications for weight loss or diabetes
- You do not have any other major medical conditions that could make the trial unsafe for you
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a new medicine called ALN-6222 in people with obesity to see if it's safe and how well it works. The study focuses on adults with a BMI between 30 and 40 who don't have diabetes.
This trial tests whether an experimental drug (LY3437943) can help people with obesity or overweight lose weight. It compares the drug to a placebo (inactive shot), and you must be willing to give yourself daily injections.
This trial tests an experimental drug (Eloralintide) to see if it can help with weight management. It is for people who have a body mass index (BMI) between 25 and 45 and stable weight.
This study tests a new daily pill (aleniglipron) to help adults with excess weight and type 2 diabetes lose weight and improve blood sugar control. It may be a good fit if you have a BMI of 27 or higher and your diabetes is managed with A1c between 6.5% and 10%.
This clinical trial tests new treatments for adults who are overweight or have obesity. The goal is to help people lose weight and improve their health.
This trial tests if tirzepatide, a diabetes and weight loss medication, can help improve fatty liver disease in people who are overweight or have obesity. It may offer a new treatment option for managing liver health.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.